In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 629 ( 2022-01-26)
Abstract:
Vaccines against SARS-CoV-2 are especially important for protecting older adults who are at the highest risk of developing severe COVID-19. To address this, Nanishi et al. tested a receptor binding domain (RBD) protein subunit vaccine with a variety of adjuvants to find which combination best protected aged mice. The authors found that combining RBD with aluminum hydroxide (AH) and CpG resulted in a highly immunogenic vaccine that was protective in young and aged mice. The authors also showed that AH:CpG induced robust innate immune responses in peripheral blood mononuclear cells isolated from older adults. This vaccine is also scalable and could be deployed to low- and middle-income countries.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abj5305
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022